condoliase
Trade name: Hernicore
Biologicalexperimental
Condoliase (Hernicore) is a biopharmaceutical for the treatment of lumbar disc herniation. Clinical trials have shown its benefit in alleviation of lumbar disc herniation associated low back pain and disability, although some concerns have been suggested with regard to promotion of disc degeneration. — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT01282606)
Timeline
Indications
Mechanism of action
- Hyaluronic acidHYDROLYTIC ENZYME
Hyaluronic acid hydrolytic enzyme
- Chondroitin-6-sulfateHYDROLYTIC ENZYME
Chondroitin-6-sulfate hydrolytic enzyme
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCondoliase ↗
- ChEMBLCHEMBL2107876 ↗
Also known as
- condoliase
- condoliase
- condoliase
- si-6603
- si-6603
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03607838 | Phase 3 | May 30, 2018 | Seikagaku Corporation |
| NCT02421601 | Phase 3 | Mar 1, 2015 | Seikagaku Corporation |
| NCT01941563 | Phase 3 | Sep 1, 2013 | Seikagaku Corporation |
| NCT00634946 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2008 | Seikagaku Corporation |
| NCT01282606 | Phase 2 | Dec 1, 2007 | Seikagaku Corporation |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seikagaku Corporation | For profit | 5 | 5 | 2 | 2007 |
1 organizations
Page 1 / 1